FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129537981> ?p ?o ?g. }

• W2129537981 endingPage "338" @default.
• W2129537981 startingPage "331" @default.
• W2129537981 abstract "Purpose Epidermal growth factor receptor (EGFR) overexpression has been consistently found to be an independent predictor of local-regional relapse (LRR) after radiotherapy. We assessed the extent by which it can refine risk classification for overall survival (OS) and LRR in patients with head-and-neck squamous cell carcinoma (HNSCC). Methods and Materials EGFR expression in locally advanced HNSCC was measured by immunohistochemistry in a series of patients randomized to receive accelerated or conventional radiation regimens in a Phase III trial. Subsequently, data of the two series were pooled (N = 533) for conducting a recursive partitioning analysis that incorporated clinical parameters (e.g., performance status, primary site, T and N categories) and four molecular markers (EGFR, p53, Ki-67, and microvessel density). Results This study confirmed that patients with higher than median levels of tumor EGFR expression had a lower OS (relative risk [RR]: 1.90, p = 0.0010) and a higher LRR (RR: 1.91, p = 0.0163). Of the four markers analyzed, only EGFR was found to contribute to refining classification of patients into three risk classes with distinct OS and LRR outcomes. The addition of EGFR to three clinical parameters could identify patients having up to a fivefold difference in the risk of LRR. Conclusions Adding pretreatment EGFR expression data to known robust clinical prognostic variables improved the estimation of the probability for OS and LRR after radiotherapy. Its use for stratifying or selecting patients with defined tumor feature and pattern of relapse for enrollment into clinical trials testing specific therapeutic strategy warrants further investigation. Epidermal growth factor receptor (EGFR) overexpression has been consistently found to be an independent predictor of local-regional relapse (LRR) after radiotherapy. We assessed the extent by which it can refine risk classification for overall survival (OS) and LRR in patients with head-and-neck squamous cell carcinoma (HNSCC). EGFR expression in locally advanced HNSCC was measured by immunohistochemistry in a series of patients randomized to receive accelerated or conventional radiation regimens in a Phase III trial. Subsequently, data of the two series were pooled (N = 533) for conducting a recursive partitioning analysis that incorporated clinical parameters (e.g., performance status, primary site, T and N categories) and four molecular markers (EGFR, p53, Ki-67, and microvessel density). This study confirmed that patients with higher than median levels of tumor EGFR expression had a lower OS (relative risk [RR]: 1.90, p = 0.0010) and a higher LRR (RR: 1.91, p = 0.0163). Of the four markers analyzed, only EGFR was found to contribute to refining classification of patients into three risk classes with distinct OS and LRR outcomes. The addition of EGFR to three clinical parameters could identify patients having up to a fivefold difference in the risk of LRR. Adding pretreatment EGFR expression data to known robust clinical prognostic variables improved the estimation of the probability for OS and LRR after radiotherapy. Its use for stratifying or selecting patients with defined tumor feature and pattern of relapse for enrollment into clinical trials testing specific therapeutic strategy warrants further investigation." @default.
• W2129537981 created "2016-06-24" @default.
• W2129537981 creator A5003374263 @default.
• W2129537981 creator A5011367592 @default.
• W2129537981 creator A5013341404 @default.
• W2129537981 creator A5016127308 @default.
• W2129537981 creator A5036014755 @default.
• W2129537981 creator A5039837606 @default.
• W2129537981 creator A5055986604 @default.
• W2129537981 creator A5056841878 @default.
• W2129537981 creator A5060545257 @default.
• W2129537981 creator A5061375711 @default.
• W2129537981 creator A5065416384 @default.
• W2129537981 date "2011-10-01" @default.
• W2129537981 modified "2023-09-26" @default.
• W2129537981 title "Integrating Epidermal Growth Factor Receptor Assay With Clinical Parameters Improves Risk Classification for Relapse and Survival in Head-and-Neck Squamous Cell Carcinoma" @default.
• W2129537981 cites W1500857863 @default.
• W2129537981 cites W1903247072 @default.
• W2129537981 cites W1968366677 @default.
• W2129537981 cites W1970170556 @default.
• W2129537981 cites W1987705911 @default.
• W2129537981 cites W1993427672 @default.
• W2129537981 cites W2005204942 @default.
• W2129537981 cites W2020600496 @default.
• W2129537981 cites W2021907516 @default.
• W2129537981 cites W2022775755 @default.
• W2129537981 cites W2025974334 @default.
• W2129537981 cites W2030489665 @default.
• W2129537981 cites W2031648200 @default.
• W2129537981 cites W2036005555 @default.
• W2129537981 cites W2048787136 @default.
• W2129537981 cites W2059568450 @default.
• W2129537981 cites W2075816930 @default.
• W2129537981 cites W2090644399 @default.
• W2129537981 cites W2094337557 @default.
• W2129537981 cites W2100961085 @default.
• W2129537981 cites W2120068217 @default.
• W2129537981 cites W2136871952 @default.
• W2129537981 cites W2139554459 @default.
• W2129537981 cites W2141592118 @default.
• W2129537981 cites W2145078756 @default.
• W2129537981 cites W2145478177 @default.
• W2129537981 cites W2151415400 @default.
• W2129537981 cites W2163186602 @default.
• W2129537981 cites W2171524637 @default.
• W2129537981 cites W2319962899 @default.
• W2129537981 cites W3041047318 @default.
• W2129537981 cites W4247128285 @default.
• W2129537981 cites W4247452643 @default.
• W2129537981 doi "https://doi.org/10.1016/j.ijrobp.2010.05.024" @default.
• W2129537981 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2992592" @default.
• W2129537981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20732768" @default.
• W2129537981 hasPublicationYear "2011" @default.
• W2129537981 type Work @default.
• W2129537981 sameAs 2129537981 @default.
• W2129537981 citedByCount "48" @default.
• W2129537981 countsByYear W21295379812012 @default.
• W2129537981 countsByYear W21295379812013 @default.
• W2129537981 countsByYear W21295379812014 @default.
• W2129537981 countsByYear W21295379812015 @default.
• W2129537981 countsByYear W21295379812016 @default.
• W2129537981 countsByYear W21295379812017 @default.
• W2129537981 countsByYear W21295379812018 @default.
• W2129537981 countsByYear W21295379812019 @default.
• W2129537981 countsByYear W21295379812020 @default.
• W2129537981 countsByYear W21295379812021 @default.
• W2129537981 countsByYear W21295379812022 @default.
• W2129537981 countsByYear W21295379812023 @default.
• W2129537981 crossrefType "journal-article" @default.
• W2129537981 hasAuthorship W2129537981A5003374263 @default.
• W2129537981 hasAuthorship W2129537981A5011367592 @default.
• W2129537981 hasAuthorship W2129537981A5013341404 @default.
• W2129537981 hasAuthorship W2129537981A5016127308 @default.
• W2129537981 hasAuthorship W2129537981A5036014755 @default.
• W2129537981 hasAuthorship W2129537981A5039837606 @default.
• W2129537981 hasAuthorship W2129537981A5055986604 @default.
• W2129537981 hasAuthorship W2129537981A5056841878 @default.
• W2129537981 hasAuthorship W2129537981A5060545257 @default.
• W2129537981 hasAuthorship W2129537981A5061375711 @default.
• W2129537981 hasAuthorship W2129537981A5065416384 @default.
• W2129537981 hasBestOaLocation W21295379812 @default.
• W2129537981 hasConcept C121608353 @default.
• W2129537981 hasConcept C126322002 @default.
• W2129537981 hasConcept C137345334 @default.
• W2129537981 hasConcept C141071460 @default.
• W2129537981 hasConcept C143998085 @default.
• W2129537981 hasConcept C204232928 @default.
• W2129537981 hasConcept C2776530083 @default.
• W2129537981 hasConcept C2776833033 @default.
• W2129537981 hasConcept C2777506169 @default.
• W2129537981 hasConcept C2779438470 @default.
• W2129537981 hasConcept C3018411727 @default.
• W2129537981 hasConcept C509974204 @default.
• W2129537981 hasConcept C535046627 @default.
• W2129537981 hasConcept C71924100 @default.
• W2129537981 hasConceptScore W2129537981C121608353 @default.
• W2129537981 hasConceptScore W2129537981C126322002 @default.
• W2129537981 hasConceptScore W2129537981C137345334 @default.

• next